ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
H.C. Wainwright 4 th Annual Kidney Virtual Conference
Date: Monday, July 14, 2025
Time: 1:30pm ET
Format: Fireside Chat
Webcast: Link
The live webcast will be accessible through the 'Events' section of the Investor Relations tab within ProKidney's website at www.prokidney.com. Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT ®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
Elevance Health, Inc. ELV is set to report its second-quarter 2025 results on July 17, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings is currently pegged at $9.20 per share on revenues of $48.13 billion. The second-quarter earnings estimate declined 1.8% over the past 60 days. The bottom-line projection indicates a year-over-year decline of 9.1%. However, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year increase of 11.4%. For 2025, the Zacks Consensus Estimate for Elevance's revenues is pegged at $195 billion, implying a rise of 11.3% year over year. The consensus mark for 2025 EPS is pegged at $34.40, implying a 4.1% year-over-year increase. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Elevance's earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being negative 1.2%. This is depicted in the figure below. Elevance Health, Inc. Price and EPS Surprise Q2 Earnings Whispers for Elevance Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here. ELV has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. What's Shaping Elevance's Q2 Results? The Zacks Consensus Estimate for product revenues indicates 11.1% growth from the year-ago period's $5.5 billion. The consensus estimate for premiums indicates an 11.9% increase from the year-ago period. These are likely to have aided revenues in the second quarter. The consensus mark for Commercial Individual membership implies 5.9% growth from a year ago, while our model estimate indicates a 5.6% increase. However, the consensus estimate for Commercial Fee-based memberships indicates a 0.1% year-over-year decline. Meanwhile, the Zacks Consensus Estimate for Carelon brand's operating income for the second quarter indicates a 14.1% year-over-year increase. Growth in CarelonRx is primarily expected to have aided the brand. The results are likely to have been supported by the recent buyouts in home health and pharmacy services. However, its expenses are likely to have remained elevated in the quarter due to substantial investments in digital capabilities and platforms. High benefit expenses, cost of products sold and interest expenses are likely to have affected profit margins, making earnings beat uncertain. The Zacks Consensus Estimate for the benefit expense ratio is pegged at 88.4, higher than the year-ago level of 86.3. We expect total expenses to jump nearly 11% year over year in the second quarter. The Zacks Consensus Estimate for the Health Benefits segment's operating income for the second quarter indicates a 12.4% year-over-year decrease. Also, declining memberships in Medicaid are likely to have kept second-quarter premium growth in check. Stocks That Warrant a Look While an earnings beat looks uncertain for Elevance, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around: Boston Scientific Corporation BSX has an Earnings ESP of +0.88% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Boston Scientific's bottom line for the to-be-reported quarter indicates a 16.1% year-over-year growth. Boston Scientific's earnings beat estimates in each of the last four quarters, with an average surprise of 8.8%. CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2. The Zacks Consensus Estimate for CVS Health's bottom line for the to-be-reported quarter is pegged at $1.47. CVS Health's earnings beat estimates in each of the past four quarters, with an average surprise of 18.1%. Summit Therapeutics Inc. SMMT has an Earnings ESP of +6.25% and a Zacks Rank of 2. The Zacks Consensus Estimate for Summit Therapeutics' bottom line for the to-be-reported quarter has witnessed one upward estimate revision in the past 60 days with no opposite movement. Summit Therapeutics' earnings beat estimates in two of the trailing four quarters, met once and missed on the other occasion, with an average surprise of 3.1%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report
Globe and Mail
32 minutes ago
- Globe and Mail
Astera Labs Drops 33% Year to Date: Buy, Sell or Hold the Stock?
Astera Labs ALAB shares have dropped 32.8% year to date (YTD), outperforming the Zacks Internet Software industry's return of 14.1% and the Zacks Computer and Technology sector's growth of 7.5%. Shares of this semiconductor company have underperformed close peers, including Broadcom AVGO and Credo Technology CRDO, which appreciated 17.5% and 43.7%, respectively, YTD. Stiff competition, along with uncertainty over tariffs, has negatively impacted ALAB's YTD performance. Astera Labs is facing stiff competition from both Broadcom and Credo Technology. Broadcom's launch of PCIe Gen 6 portfolio, featuring high-port switches and retimers tested for interoperability with partners like Micron and Teledyne LeCroy, is a noteworthy development. Credo Technology continues to gain share in the optical segment, with a major DSP win for an 800G transceiver and the launch of ultra-low-power optical DSPs based on 5nm technology. It also reported a healthy pipeline of PCIe Gen6 AECs and retimers, with further customer wins expected to support fiscal 2026 growth. However, Astera Labs' expanding portfolio is expected to help the stock recover in the remainder of 2025. ALAB Stock's Performance Strong Portfolio to Boost ALAB's Prospects Astera Labs has emerged as a key player in next-gen data center connectivity with a full-stack portfolio spanning PCIe 6.0, Ultra Accelerator (UA) Link, and CXL 3.0. Apart from shipping PCIe Gen 6 Scorpio P-Series Smart Fabric Switches, Aries 6 PCIe/CXL Smart Retimers, and Aries 6 PCIe Smart Cable Modules, the company added Aries 6 PCIe Smart Gearboxes. Astera Labs is benefiting from strong demand for Aries and Taurus product families, both expected to grow on a sequential basis in the second quarter of 2025. The addition of PCIe 6 over Optics Technology is noteworthy. Diversification across both GPU and custom ASIC-based systems for a variety of applications, including scale-up and scale-out connectivity, is a key catalyst for ALAB's Aries product family. Continued deployment of AI and general-purpose systems at leading hyperscaler customers is benefiting the Taurus system. Astera Labs plans to provide a broad portfolio of connectivity solutions for the entire AI rack through purpose-built silicon hardware and software to support computing platforms based on both custom ASICs and merchant GPUs is a key catalyst. The company plans to increase its research and development (R&D) investments to achieve these plans. In first-quarter 2025, R&D jumped 20% year over year to $64.6 million. Operating expense is expected to be between $73 million and $75 million in the second quarter of 2025, driven by higher R&D expenses. UA Link offers a significant growth opportunity for Astera Labs. UA Link combines the memory semantics of PCIe and the fast speed of Ethernet, but is devoid of the software complexity and performance limitations of Ethernet. ALAB expects to deliver UA Link solutions in 2026 to solve scale-up connectivity challenges for next-generation AI infrastructure. The growing proliferation of UA Link is expected to be a multibillion-dollar additional market opportunity for Astera Labs by 2029. Expanding Partner Base Bodes Well for ALAB Astera Labs is benefiting from a rich partner base. ALAB is advancing next-gen data center infrastructure with the introduction of a PCIe 6-ready reference design based on NVIDIA NVDA Blackwell-based MGX platform that leverages Scorpio Smart Fabric Switches for AI and cloud infrastructure. Scorpio-based solutions enable users to maximize GPU productivity through enhanced data center observability, telemetry, and diagnostics using ALAB's COSMOS rack-scale management software. Astera Labs has showcased the first end-to-end PCIe 6 interoperability with NVIDIA's Blackwell GPU and Micron's NVMe SSD, with both Aries 6 PCIe Smart Retimer and Scorpio-P PCIe SmartFabric Switch. Collaboration with ecosystem leaders like Wistron expands Astera Lab's reach into OEM and modular platforms. ALAB Offers Positive Q2 Guidance Astera Labs expects second-quarter 2025 revenues between $170 million and $175 million, suggesting an increase between 7% and 10% year over year. The company expects accelerated shipments of Scorpio P-Series switches and Aries 6 retimers on a customized rack-scale AI platform based on market-leading GPUs to boost top-line growth. Scorpio revenues are expected to grow sequentially in the second quarter and should account for 10% of total revenues in 2025. The Zacks Consensus Estimate for second-quarter 2025 revenues is pegged at $172.71 million, indicating 124.74% year-over-year growth. Earnings are expected between 32 cents and 33 cents per share for the second quarter. The consensus mark for earnings is pegged at 33 cents per share, unchanged over the past 30 days, indicating 153.85% year-over-year growth. The Zacks Consensus Estimate for 2025 revenues stands at $702.43 million, suggesting 77.25% growth over 2024's reported figure. The consensus mark for earnings is pegged at $1.35 per share, unchanged over the past 30 days, but indicates 60.71% year-over-year growth. ALAB Shares Trading at a Premium Astera Labs stock is trading at a premium, as suggested by the Value Score of F. In terms of the forward 12-month Price/Sales, ALAB is trading at 19.49X, higher than the sector's 6.59X, Broadcom's 18.03X but lower than Credo Technology's 19.95X. Price/Sales Ratio (F12M) Conclusion Although Astera Labs' innovative portfolio is noteworthy, its prospects suffer from tariff uncertainty and stiff competition, along with a stretched valuation. Astera Labs currently carries a Zacks Rank #3 (Hold), which implies that investors should wait for a more favorable point to accumulate the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA): Free Stock Analysis Report Broadcom Inc. (AVGO): Free Stock Analysis Report Credo Technology Group Holding Ltd. (CRDO): Free Stock Analysis Report Astera Labs, Inc. (ALAB): Free Stock Analysis Report
Globe and Mail
33 minutes ago
- Globe and Mail
Wall Street hangs near its record amid doubts about Trump's tariffs
NEW YORK (AP) — U.S. stock indexes are hanging near their records on Monday following President Donald Trump's latest updates to his tariffs, as speculation continues on Wall Street that he may ultimately back down on them. The S&P 500 was edging up by 0.1% and within 0.3% of its all-time high set on Thursday. The Dow Jones Industrial Average was up 35 points, or 0.1%, as of 11:30 a.m. Eastern time, and the Nasdaq composite was 0.2% higher. Stock indexes elsewhere around the world were mixed in their first trading after Trump announced plans over the weekend for 30% tariffs on goods from Mexico and the European Union. They won't take effect until Aug. 1, the same deadline that Trump announced last week for updated tax rates on imports from Japan, South Korea and a dozen other countries. The latest postponements for Trump's tariffs allows more time for him to reach trade deals with other countries that could lower the tariff rates and prevent pain for international trade. They also feed into speculation that Trump may ultimately back down on his tariffs if they end up creating too much damage for the economy and for financial markets. If Trump were to enact all his proposed tariffs on Aug. 1, they would raise the risk of a recession. That would not only hurt U.S. voters but also raise the pressure on the U.S. government's debt level relative to the economy's size, particularly after Washington approved big tax cuts that will add to the deficit. 'We therefore believe that the administration is using this latest round of tariff escalation to maximize its negotiating leverage and that it will ultimately de-escalate, especially if there is a new bout of heightened bond and stock market volatility,' according to Ulrike Hoffmann-Burchardi, global head of equities at UBS Global Wealth Management. 'As usual, there are many conditions and clauses that can get these rates reduced,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'That's probably why the market might not like the tariff talk, but it's not panicking about it either.' For the time being, all the uncertainty around tariffs could help keep markets unsteady. This upcoming week has several potential flashpoints that could shake things. On Tuesday will come the latest reading on inflation across the United States. Economists expect it to show inflation accelerated to 2.6% last month from 2.4% in May. Companies are also lining up to report how they performed during the spring. JPMorgan Chase and several other huge banks will report their latest quarterly results on Tuesday, followed by Johnson & Johnson on Wednesday and PepsiCo on Thursday. Fastenal, a distributor of industrial and construction supplies, on Monday reported a stronger profit for the latest quarter than analysts expected. Its stock rose 2.7%, though it also said that market conditions remain sluggish. Shares of Kenvue rose 0.5% in shaky trading after the former division of Johnson & Johnson said CEO Thibaut Mongon is stepping down. Kenvue, the maker of Listerine and Band-Aid brands, is in the midst of a strategic review of its options, 'including ways to simplify the company's portfolio and how it operates,' according to Larry Merlo, the board's chair. Waters slumped 11% after saying it had agreed to merge with Becton, Dickinson and Co.'s biosciences and diagnostic solutions business in a deal valued at roughly $17.5 billion. In the bond market, Treasury yields held relatively steady. The yield on the 10-year Treasury rose to 4.44% from 4.43% late Friday. In stock markets abroad, indexes fell across much of Europe. Germany's DAX lost 0.5%, and France's CAC 40 fell 0.4%. But indexes rose 0.8% in South Korea and 0.3% in Hong Kong. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of the Aug. 1 deadline for reaching a new trade deal with Washington. Some of the biggest moves in financial markets were for crypto, where bitcoin continues to set records. This upcoming week is 'Crypto Week' in Washington, where Congress will consider several bills to 'make America the crypto capital of the world.'
